About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Phase II Study of AS1411 in Renal Cell Carcinoma

NCT00740441·7 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Antisoma Research

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Histologically or cytologically confirmed renal cell carcinoma containing predominant clear cell histology
Failed or intolerant to 1 or more previous lines of treatments (which must include a Tyrosine Kinase Inhibitor)

You may not be if

Collecting duct histology
A history of bleeding disorders or currently taking oral vitamin K antagonise medication
Unstable brain metastases
History of prior or concomitant malignancy (except for curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other cancer for which the patient has been disease free for 3 years)

The record

StatusUnknown

PhasePhase 2

Taking part30

StartedAug 2008

UpdatedSep 25, 2009

Conditions

Metastatic Renal Cell Carcinoma

Where7

City of Hope
Duarte, California, United States
University of California, Davis Cancer Center
Sacramento, California, United States
University of California San Francisco
San Francisco, California, United States

Clareo Health | A Phase II Study of AS1411 in Renal Cell Carcinoma